BENGALURU: India's fifth-largest IT services company Tech Mahindra said it will acquire Virginia, US-based Lightbridge Communications Corporation (LCC) for $240 million (over Rs 1,400 crore), making it the largest overseas acquisition it has ever ... Times of India, 4 days ago
TechM buys US network services firm for $240m - The Financial Chronicle, 4 days ago
Tech Mahindra : acquires US company for $240m - 4 Traders, 3 days ago
1 images for "sarabjit kour nangra"
— By | Nov 21, 2014 01:09 am With An Annual Revenue Of About $430 Mn, Lightbridge Communications Will Help The Country's Fifth-Largest Software Services Firm Strengthen Its Presence In The Fast-Growing Telecom And Enterprises Network Market New ...The Freepress Journal, 3 days ago Tech Mahindra to buy LCC for $240 mn in largest Indian IT deal this year Samaylive, 3 days ago Tech Mahindra buys US company for 240 million Hindustan Times, 3 days ago Tech Mahindra buys LCC for $240 million in largest Indian IT deal this year DNA India, 4 days ago
Mumbai : Ranbaxy Laboratories , the company in waiting to be merged with Sun Pharma, has taken a legal recourse against the US drug regulator for revoking the tentative approvals granted for launching the generic versions of AstraZeneca's heartburn ...4 Traders, 4 days ago Ranbaxy files suit against USFDA for revoking approved drugs DNA India, 5 days ago Ranbaxy sues FDA for revoking approvals [DNA : Daily News & Analysis (India)] Pharmacy Choice, 4 days ago Double blow to Ranbaxy Calcutta Telegraph, 2 weeks ago
In a setback, the US court has denied a request by drug-maker Ranbaxy Laboratories to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche€s antiviral Valcyte. Ranbaxy had sought the restraining order against ...MyIris, 4 days ago
For long at the receiving end, Ranbaxy Laboratories Ltd has chosen to go on the offensive against the United States Food and Drug Administration (USFDA), suing the US regulator for revoking tentative approvals given to it six years ago to launch ...Hindu Business Line, 6 days ago Ranbaxy sues USFDA for revoking approvals for 2 drugs; stk down Economic Times, 5 days ago
closed down by 2.45 per cent, wiping out Rs 1,228.13 crore from its market valuation, as the company's September quarter results were "below" market expectations. Cipla fell by 2.93 per cent to Rs 605.85 in day trade before closing at Rs 608.85, ...Business Standard India, 1 week ago Cipla shares fall as second quarter numbers disappoint Business Today India, 1 week ago Cipla shares fall almost 3% post Q2 results Hindu Business Line, 1 week ago
More from: , India TV...and 3 other sources
S Cipla's scrip lost 2.93 percent to Rs 605.85 at the BSE. At the NSE, it was down 2.67 percent to Rs 606.95. "Cipla posted results for Q2 FY15 below expectations on all fronts," said Sarabjit Kour Nangra, VP Research - Pharma, Angel Broking. ...Moneycontrol.com, 1 week ago Cipla falls 2.93% post Q2 results on below expected numbers Moneycontrol.com, 1 week ago
On Thursday, Sun Pharma ended at Rs. 908.60 on the BSE, up 0.26% from the previous close. Photo: Hemant Mishra/Mint New Delhi/Mumbai: India's largest drug maker by revenue Sun Pharmaceuticals Industries Ltd on Thursday reported a 15.4% increase in ...Livemint.com, 1 week ago IPCA's US FDA woes raises huge concern Business Standard India, 2 weeks ago IPCA Laboratories stock slumps 16 per cent Economic Times, 2 weeks ago IPCA Lab stock slumps 16 per cent Business Standard India, 2 weeks ago
More from: , Hindu Business Line...and 2 other sources
New Delhi: Indian drug maker Aurobindo Pharma Ltd has emerged the highest bidder in a bankruptcy auction of nutritional supplement maker Natrol Inc. and its affiliates. The Hyderabad-based firm made the $132.5 million offer via its US subsidiary ...India Brand Equity Foundation, 1 week ago Aurobindo set to buy Natrol for $132.5 million Financial Chronicle, 1 week ago Aurobindo Pharma emerges top bidder to buy Natrol Inc for $132.5 million Economic Times, 1 week ago
Drug maker Dr Reddy's Laboratories today said the company is all set to launch generic version of Valcyte (Valacyclovir Hydrochloride) in the US market soon.Valganciclovir Hydrochloride is prescribed to patients with acquired immunodeficiency ...DNA India, 2 weeks ago Dr Reddy's to launch generic version of Valcyte in US market The Financial Chronicle, 2 weeks ago Dr Reddys to launch generic Valcyte in US; shares soar 4.4% Business Standard India, 2 weeks ago Dr Reddy's to launch generic Valcyte in US; shares soar 4.4% Business Standard India, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!